|
1
|
Cataldo VD, Gibbons DL, Pérez-Soler R and
Quintás-Cardama A: Treatment of non-small-cell lung cancer with
erlotinib or gefitinib. N Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coley WB: The treatment of malignant
tumors by repeated inoculations of erysipelas. With a report of ten
original cases. 1893. Clin Orthop Relat Res. 262:3–11.
1991.PubMed/NCBI
|
|
4
|
Rosenberg SA, Lotze MT, Muul LM, Leitman
S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E,
Vetto JT, et al: Observations on the systemic administration of
autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med.
313:1485–1492. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Atzpodien J, Kirchner H, Jonas U, Bergmann
L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller
SC, et al: Prospectively Randomized Trial of the German Cooperative
Renal Carcinoma Chemoimmunotherapy Group (DGCIN): Interleukin-2-
and interferon alfa-2a-based immunochemotherapy in advanced renal
cell carcinoma: A Prospectively Randomized Trial of the German
Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J
Clin Oncol. 22:1188–1194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schuler G, Schuler-Thurner B and Steinman
RM: The use of dendritic cells in cancer immunotherapy. Curr Opin
Immunol. 15:138–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finn OJ: Cancer vaccines: Between the idea
and the reality. Nat Rev Immunol. 3:630–641. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu G, Yang W, Guo M, Liu X, Huang N, Li
D, Jiang Z, Yang W, Zhang W, Su H, et al: Effective modulation of
CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients
by combination of interferon-α and interleukin-2. Cancer Immunol
Immunother. 61:2357–2366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valzasina B, Piconese S, Guiducci C and
Colombo MP: Tumor-induced expansion of regulatory T cells by
conversion of CD4+CD25- lymphocytes is thymus and proliferation
independent. Cancer Res. 66:4488–4495. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jarnicki AG, Lysaght J, Todryk S and Mills
KH: Suppression of antitumor immunity by IL-10 and
TGF-beta-producing T cells infiltrating the growing tumor:
Influence of tumor environment on the induction of CD4+ and CD8+
regulatory T cells. J Immunol. 177:896–904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vesely MD, Kershaw MH, Schreiber RD and
Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev
Immunol. 29:235–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: Linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trzonkowski P, Szmit E, Myśliwska J,
Dobyszuk A and Myśliwski A: CD4+CD25+ T regulatory cells inhibit
cytotoxic activity of T CD8+ and NK lymphocytes in the direct
cell-to-cell interaction. Clin Immunol. 112:258–267. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gattinoni L, Powell DJ Jr, Rosenberg SA
and Restifo NP: Adoptive immunotherapy for cancer: Building on
success. Nat Rev Immunol. 6:383–393. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Loeb LA, Loeb KR and Anderson JP: Multiple
mutations and cancer. Proc Natl Acad Sci USA. 100:776–781. 2003.
View Article : Google Scholar : PubMed/NCBI
|
